Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030914 · ClinicalTrials.gov registry record · Phase 3
Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 227
- Enrollment target
NCT00030914 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 227 participants.
The verdict
NCT00030914, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 227 participants
- Enrollment target
Study Summary
RATIONALE: Medroxyprogesterone and venlafaxine may be effective in relieving hot flashes. It is not yet known whether venlafaxine is more effective than medroxyprogesterone in relieving hot flashes. PURPOSE: Randomized phase III trial to compare the effectiveness of medroxyprogesterone with that of venlafaxine in treating women who are experiencing hot flashes.
Interventions
- DRUG venlafaxine
- DRUG medroxyprogesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2002-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030914
The ClinicalTrials.gov registry entry for NCT00030914 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which venlafaxine is the first listed.
NCT00030914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030914 about?
NCT00030914 is a clinical study titled "Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women". RATIONALE: Medroxyprogesterone and venlafaxine may be effective in relieving hot flashes. It is not yet known whether venlafaxine is more effective than medroxyprogesterone in relieving hot flashes. PURPOSE: Randomized phase III trial to compare the effectiveness of medroxyprogesterone with that of...
What is the current status of trial NCT00030914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 227 participants. The study started on 2002-04. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00030914?
The interventions under investigation include: venlafaxine (DRUG), medroxyprogesterone (DRUG).
Who is sponsoring clinical trial NCT00030914?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.